Cart is empty Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to Phase II trial results published in Nature Cancer by researchers at The University of Texas MD Anderson Cancer Center.
Leave A Comment